Please use this identifier to cite or link to this item:
Title: A framework for the development of effective anti-metastatic agents.
Austin Authors: Anderson, Robin L ;Balasas, Theo;Callaghan, Juliana;Coombes, R Charles;Evans, Jeff;Hall, Jacqueline A;Kinrade, Sally;Jones, David;Jones, Paul S;Jones, Rob;Marshall, John F;Panico, Maria Beatrice;Shaw, Jacqui A;Steeg, Patricia S;Sullivan, Mark;Tong, Warwick;Westwell, Andrew D;Ritchie, James W A
Affiliation: Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Research and Innovation Services, University of Portsmouth, Portsmouth, Hampshire, UK
Commercial Partnerships, Cancer Research UK (CRUK), London, UK
Cancer Therapeutics Cooperative Research Centre (CTx), Melbourne, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia
Medicines Development for Global Health, Southbank, Victoria, Australia
Centre for Drug Development, CRUK, London, UK
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, UK
Leicester Cancer Research Centre, University of Leicester, Leicester, Leicestershire, UK
Medicines and Healthcare Products Regulatory Agency, London, UK
Queen Mary University of London, Barts Cancer Institute, London, UK
Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, UK
Centre for Drug Development, CRUK, London, UK
Research and Development, Vivacitv Ltd, Chesham, Buckinghamshire, UK
Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK
Issue Date: 2019
Date: 2018-12-04
Publication information: Nature reviews. Clinical oncology 2019; 16(3): 185-204
Abstract: Most cancer-related deaths are a result of metastasis, and thus the importance of this process as a target of therapy cannot be understated. By asking 'how can we effectively treat cancer?', we do not capture the complexity of a disease encompassing >200 different cancer types - many consisting of multiple subtypes - with considerable intratumoural heterogeneity, which can result in variable responses to a specific therapy. Moreover, we have much less information on the pathophysiological characteristics of metastases than is available for the primary tumour. Most disseminated tumour cells that arrive in distant tissues, surrounded by unfamiliar cells and a foreign microenvironment, are likely to die; however, those that survive can generate metastatic tumours with a markedly different biology from that of the primary tumour. To treat metastasis effectively, we must inhibit fundamental metastatic processes and develop specific preclinical and clinical strategies that do not rely on primary tumour responses. To address this crucial issue, Cancer Research UK and Cancer Therapeutics CRC Australia formed a Metastasis Working Group with representatives from not-for-profit, academic, government, industry and regulatory bodies in order to develop recommendations on how to tackle the challenges associated with treating (micro)metastatic disease. Herein, we describe the challenges identified as well as the proposed approaches for discovering and developing anticancer agents designed specifically to prevent or delay the metastatic outgrowth of cancer.
DOI: 10.1038/s41571-018-0134-8
ORCID: 0000-0002-6841-7422
Journal: Nature reviews. Clinical oncology
PubMed URL: 30514977
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 23, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.